drugset / Trial / NCT04063449
Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
A Controlled Clinical Study of Endostar/PD-1 Inhibitors Combined With chemotherapy(Carboplatin-Pemetrexed) as First-line Treatment for Advanced Non-squamous Cell Lung Cancer With Negative Driving Gene
Timeline
- Start
- 2019-08-20
- Primary completion
- 2020-06-30
- Completion
- 2021-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 210 mg | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |